What is AI actually changing in drug discovery—and what's simply hype?
In Episode 36 of Thoroughly Thriving, Darren and Sean sit down with Kevin Krause, President and CEO of ArrePath, for a practical conversation about biotech leadership, AI/ML-driven drug discovery, strategic decision-making, and building companies differently.
Kevin has spent more than two decades working at the intersection of science and strategy. His career has taken him from the research bench into clinical development, corporate development, commercial strategy and ultimately the CEO chair. Along the way, he contributed to seven approved antibiotics and gained a rare view of what it actually takes to move a medicine from discovery toward patients.
Today, Kevin is leading ArrePath as it applies AI and machine learning to drug discovery.
But his perspective is refreshingly straightforward:
AI isn't the product. The medicine is.
Kevin explains how machine learning can help scientists explore chemistry faster, predict multiple drug-development parameters simultaneously, reduce costs, increase creativity, and compress work that once required weeks into hours.
We discuss:
- Kevin's unconventional path from scientist to CEO
- Why strategic thinking changed his career
- A practical framework for making better decisions
- What seven drug approvals taught him about biotech strategy
- Why good drugs can still miss their market opportunity
- The importance of listening to regulators and external advisors
- How ArrePath is expanding beyond infectious disease
- How six people can manage multiple active research programs
- What AI/ML drug discovery actually looks like day-to-day
- Why AI should augment scientists rather than replace them
- Using machine learning to predict oral bioavailability and other properties
- How agentic AI can accelerate research and decision-making
- Why biotech companies need to stop simply saying "we use AI"
- How leaders can prove AI's value to boards, partners and investors
Whether you're working in biotech, pharma, drug discovery, life sciences, artificial intelligence, investment, strategy or executive leadership, this episode offers a grounded look at what AI can—and cannot—do for modern biotech.
🎧 Watch Episode 36 of Thoroughly Thriving with Kevin Krause.
Subscribe for more conversations with leaders shaping the future of healthcare, life sciences and the world of work.
- (00:00) - Meet Kevin Krause
- (01:44) - From Bench Scientist to Biotech CEO
- (03:15) - Career Experiences That Changed Everything
- (07:52) - A Framework for Better Decisions
- (10:20) - Lessons From Seven Approved Antibiotics
- (14:29) - Navigating Biotech Headwinds
- (15:47) - Repositioning an AI-Driven Biotech
- (19:49) - Building More With a Six-Person Team
- (20:44) - What AI Drug Discovery Actually Looks Like
- (23:08) - Predicting Drug Properties With Machine Learning
- (25:32) - Building Aeropath's AI Platform
- (27:58) - How to Talk About AI Without the Hype
- (29:28) - AI Is Becoming a Commodity
- (31:49) - Proving AI's Real Value
- (32:40) - Leadership Takeaways
- (35:08) - Closing Thoughts
What is Thoroughly Thriving?
"Thoroughly Thriving" explores human capital solutions at the crossroads of talent, strategy, and innovation. Hosted by Darren Thevathasan and Sean Burroughs, the podcast offers insights on recruitment trends, business growth, and cutting-edge strategies. Each episode features discussions on innovative recruitment models, industry best practices, and personal experiences from the hosts and expert guests. It’s a valuable resource for executives, entrepreneurs, and professionals seeking to stay ahead in a dynamic job market. Practical advice to drive professional and organizational growth.